{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:39:09Z","timestamp":1788255549075,"version":"build-2803163510"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2019-12369158"],"award-info":[{"award-number":["RF-2019-12369158"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bcp.2024.116254","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T22:03:09Z","timestamp":1714687389000},"page":"116254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Non-oncogene dependencies: Novel opportunities for cancer therapy"],"prefix":"10.1016","volume":"228","author":[{"given":"Tiziana","family":"Di Marco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Cassinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2024.116254_b0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2024.116254_b0020","doi-asserted-by":"crossref","unstructured":"Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017 Jul 21;357(6348):eaal2380.","DOI":"10.1126\/science.aal2380"},{"issue":"5","key":"10.1016\/j.bcp.2024.116254_b0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc1360","article-title":"The discovery of receptor tyrosine kinases: targets for cancer therapy","volume":"4","author":"Gschwind","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0030","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008912","article-title":"Receptor tyrosine kinases: Legacy of the first two decades","volume":"6","author":"Schlessinger","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bcp.2024.116254_b0035","doi-asserted-by":"crossref","unstructured":"Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002 Jul 5;297(5578):63\u20134.","DOI":"10.1126\/science.1073096"},{"issue":"8","key":"10.1016\/j.bcp.2024.116254_b0040","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ncponc0558","article-title":"Mechanisms of disease: Oncogene addiction\u2013a rationale for molecular targeting in cancer therapy","volume":"3","author":"Weinstein","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.bcp.2024.116254_b0045","doi-asserted-by":"crossref","unstructured":"Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008 May 1;68(9):3077\u201380; discussion 3080.","DOI":"10.1158\/0008-5472.CAN-07-3293"},{"issue":"24","key":"10.1016\/j.bcp.2024.116254_b0050","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1101\/gad.1609907","article-title":"Oncogene addiction: Setting the stage for molecularly targeted cancer therapy","volume":"21","author":"Sharma","year":"2007","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.bcp.2024.116254_b0055","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cell.2021.02.020","article-title":"An expanded universe of cancer targets","volume":"184","author":"Hahn","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2024.116254_b0060","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: Oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"issue":"3\u20134","key":"10.1016\/j.bcp.2024.116254_b0065","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1615\/CritRevOncog.2016016966","article-title":"Strategies to strike survival networks in cancer","volume":"21","author":"Pennati","year":"2016","journal-title":"Crit. Rev. Oncog."},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.15252\/embr.201439949","article-title":"Oncogene addiction: Pathways of therapeutic response, resistance, and road maps toward a cure","volume":"16","author":"Pagliarini","year":"2015","journal-title":"EMBO Rep."},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0075","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.cell.2007.09.007","article-title":"Non-oncogene addiction and the stress phenotype of cancer cells","volume":"130","author":"Solimini","year":"2007","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bcp.2024.116254_b0080","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.15252\/embr.201643030","article-title":"Drugging the addict: non-oncogene addiction as a target for cancer therapy","volume":"17","author":"Nagel","year":"2016","journal-title":"EMBO Rep."},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0085","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tips.2014.01.001","article-title":"Exploiting epigenetic vulnerabilities for cancer therapeutics","volume":"35","author":"Mair","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2024.116254_b0090","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","article-title":"Targeting the cancer epigenome for therapy","volume":"17","author":"Jones","year":"2016","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3892\/or.2023.8496","article-title":"Modulating epigenetic modifications for cancer therapy (Review)","volume":"49","author":"Castro-Mu\u00f1oz","year":"2023","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2024.116254_b0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bcp.2024.116254_b0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/BTT.S326422","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biol. Targets Ther."},{"issue":"4","key":"10.1016\/j.bcp.2024.116254_b0115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.molcel.2015.04.028","article-title":"Choosing the right tool for the job: RNAi, TALEN, or CRISPR","volume":"58","author":"Boettcher","year":"2015","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.bcp.2024.116254_b0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/17460441.2016.1165203","article-title":"The development of high-content screening (HCS) technology and its importance to drug discovery","volume":"11","author":"Fraietta","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"issue":"12","key":"10.1016\/j.bcp.2024.116254_b0125","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/s41588-023-01557-x","article-title":"Complex synthetic lethality in cancer","volume":"55","author":"Ryan","year":"2023","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.bcp.2024.116254_b0130","doi-asserted-by":"crossref","first-page":"e47086","DOI":"10.1371\/journal.pone.0047086","article-title":"An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer","volume":"7","author":"Sethi","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/15548627.2016.1246107","article-title":"New anti-cancer molecules targeting HSPA5\/BIP to induce endoplasmic reticulum stress, autophagy and apoptosis","volume":"13","author":"Cerezo","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.bcp.2024.116254_b0140","doi-asserted-by":"crossref","first-page":"134","DOI":"10.18632\/oncoscience.549","article-title":"VTT-006, an anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth in vitro","volume":"8","author":"Laine","year":"2021","journal-title":"Oncoscience"},{"issue":"33","key":"10.1016\/j.bcp.2024.116254_b0145","doi-asserted-by":"crossref","first-page":"34629","DOI":"10.18632\/oncotarget.5282","article-title":"Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening","volume":"6","author":"Anania","year":"2015","journal-title":"Oncotarget"},{"issue":"410","key":"10.1016\/j.bcp.2024.116254_b0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2017.09.024","article-title":"Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells","volume":"1","author":"Anania","year":"2017","journal-title":"Cancer Lett."},{"issue":"442","key":"10.1016\/j.bcp.2024.116254_b0155","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.canlet.2018.11.010","article-title":"Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells","volume":"1","author":"Cetti","year":"2019","journal-title":"Cancer Lett."},{"issue":"44","key":"10.1016\/j.bcp.2024.116254_b0160","doi-asserted-by":"crossref","first-page":"71182","DOI":"10.18632\/oncotarget.11511","article-title":"A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct","volume":"7","author":"Ocasio","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0165","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1038\/s41598-018-23246-0","article-title":"Identification of new inhibitors against human Great wall kinase using in silico approaches","volume":"8","author":"Ammarah","year":"2018","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bcp.2024.116254_b0170","first-page":"647","article-title":"Discovery and characterization of a novel MASTL inhibitor MKI-2 targeting MASTL-PP2A in breast cancer cells and oocytes","volume":"14","author":"Kang","year":"2021","journal-title":"Pharm. Basel Switz."},{"key":"10.1016\/j.bcp.2024.116254_b0175","doi-asserted-by":"crossref","unstructured":"Martins ACF, Barbosa BM, Badenoch B, Gomes RS. Abstract B051: Design, synthesis, and in vitro evaluation of enedione derivatives as promising selective COPZ1 inhibitor. Cancer Res. 2022 Nov 15;82(22_Supplement):B051.","DOI":"10.1158\/1538-7445.PANCA22-B051"},{"key":"10.1016\/j.bcp.2024.116254_b0180","doi-asserted-by":"crossref","unstructured":"Martins AC, Barbosa BM, da Silveira IOMF, Gomes R. Abstract 4500: Enedione derivates as a potential cancer treatment through the inhibition of COPZ1. Cancer Res. 2023 Apr 4;83(7_Supplement):4500.","DOI":"10.1158\/1538-7445.AM2023-4500"},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0185","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.chembiol.2022.01.008","article-title":"Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer","volume":"29","author":"Shkedi","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bcp.2024.116254_b0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fmolb.2018.00035","article-title":"Toward developing chemical modulators of Hsp60 as potential therapeutics","volume":"5","author":"Meng","year":"2018","journal-title":"Front. Mol. Biosci."},{"issue":"7370","key":"10.1016\/j.bcp.2024.116254_b0195","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0200","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.celrep.2014.08.025","article-title":"Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition","volume":"8","author":"Bolden","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2024.116254_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2023.102323","article-title":"Bromodomain inhibitors and therapeutic applications","volume":"75","author":"Gajjela","year":"2023","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0210","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal. Transduct. Target Ther."},{"issue":"7","key":"10.1016\/j.bcp.2024.116254_b0215","first-page":"3043","article-title":"BET bromodomain inhibitors: Novel design strategies and therapeutic applications","volume":"28","author":"To","year":"2023","journal-title":"Mol. Basel Switz."},{"issue":"14","key":"10.1016\/j.bcp.2024.116254_b0220","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","article-title":"Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2024.116254_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"issue":"5","key":"10.1016\/j.bcp.2024.116254_b0230","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/1087057113476550","article-title":"Identification of small-molecule inhibitors of the ribonuclease H2 enzyme","volume":"18","author":"White","year":"2013","journal-title":"J. Biomol. Screen."},{"issue":"10","key":"10.1016\/j.bcp.2024.116254_b0235","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/acschembio.3c00191","article-title":"Targeting ribonucleases with small molecules and bifunctional molecules","volume":"18","author":"Borgelt","year":"2023","journal-title":"ACS Chem. Biol."},{"issue":"49","key":"10.1016\/j.bcp.2024.116254_b0240","doi-asserted-by":"crossref","first-page":"80901","DOI":"10.18632\/oncotarget.12646","article-title":"RNAi screens identify CHD4 as an essential gene in breast cancer growth","volume":"7","author":"D\u2019Alesio","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.celrep.2016.05.063","article-title":"In vivo functional platform targeting patient-derived xenografts identifies WDR5-Myc association as a critical determinant of pancreatic cancer","volume":"16","author":"Carugo","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0250","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acschembio.2c00843","article-title":"Discovery of potent small-molecule inhibitors of WDR5-MYC interaction","volume":"18","author":"Ding","year":"2023","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0255","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116254_b0260","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.13558\/v2\/response1","article-title":"A novel pipeline for prioritizing cancer type-specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas","author":"Sannigrahi","year":"2023","journal-title":"Mol. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2024.116254_b0265","doi-asserted-by":"crossref","first-page":"15580","DOI":"10.1038\/ncomms15580","article-title":"Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data","volume":"31","author":"Sinha","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0270","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/jcb.21077","article-title":"Acetyl-coenzyme A carboxylases: Versatile targets for drug discovery","volume":"99","author":"Tong","year":"2006","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.bcp.2024.116254_b0275","unstructured":"McDonald ER, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, et al. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell. 2017 Jul 27;170(3):577-592.e10."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0280","doi-asserted-by":"crossref","first-page":"7748","DOI":"10.1038\/s41467-022-35378-z","article-title":"Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens","volume":"13","author":"Srivatsa","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0285","doi-asserted-by":"crossref","first-page":"e202302268","DOI":"10.26508\/lsa.202302268","article-title":"Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens","volume":"7","author":"Karimpour","year":"2024","journal-title":"Life Sci. Alliance"},{"issue":"7","key":"10.1016\/j.bcp.2024.116254_b0290","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/genes14071346","article-title":"Therapeutic targeting of DNA replication stress in cancer","volume":"14","author":"Gu","year":"2023","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/1389450114666140106095432","article-title":"Targeting the BRCA1\/2 tumor suppressors","volume":"15","author":"Rosen","year":"2014","journal-title":"Curr. Drug Targets"},{"issue":"6330","key":"10.1016\/j.bcp.2024.116254_b0300","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0305","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: Enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"7825","key":"10.1016\/j.bcp.2024.116254_b0310","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41586-020-2690-1","article-title":"Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer","volume":"585","author":"Yeow","year":"2020","journal-title":"Nature"},{"issue":"7825","key":"10.1016\/j.bcp.2024.116254_b0315","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41586-020-2710-1","article-title":"TRIM37 controls cancer-specific vulnerability to PLK4 inhibition","volume":"585","author":"Meitinger","year":"2020","journal-title":"Nature"},{"issue":"265","key":"10.1016\/j.bcp.2024.116254_b0320","article-title":"Therapeutic potential of targeting polo-like kinase 4","volume":"5","author":"Lei","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2024.116254_b0325","first-page":"774","article-title":"Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors","volume":"3","author":"Coutinho","year":"2022","journal-title":"Med. N. Y. N."},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0330","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 - from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2024.116254_b0335","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41568-022-00490-1","article-title":"Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies","volume":"22","author":"Gao","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"19","key":"10.1016\/j.bcp.2024.116254_b0340","doi-asserted-by":"crossref","first-page":"e96659","DOI":"10.15252\/embj.201796659","article-title":"ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization","volume":"38","author":"Li","year":"2019","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0345","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1038\/s41467-023-37480-2","article-title":"Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0350","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41418-020-00714-7","article-title":"Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus","volume":"28","author":"Chen","year":"2021","journal-title":"Cell Death Differ."},{"issue":"14","key":"10.1016\/j.bcp.2024.116254_b0355","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.3390\/cancers13143477","article-title":"CSNK1A1, KDM2A, and LTB4R2 are new druggable vulnerabilities in lung cancer","volume":"13","author":"Sauta","year":"2021","journal-title":"Cancers"},{"issue":"231","key":"10.1016\/j.bcp.2024.116254_b0360","article-title":"Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present)","volume":"5","author":"He","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2024.116254_b0365","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"40","key":"10.1016\/j.bcp.2024.116254_b0370","article-title":"Exploiting the HSP60\/10 chaperonin system as a chemotherapeutic target for colorectal cancer","volume":"15","author":"Ray","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"30","key":"10.1016\/j.bcp.2024.116254_b0375","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1073\/pnas.1103842108","article-title":"Tumor-specific silencing of COPZ2 gene encoding coatomer protein complex subunit \u03b6 2 renders tumor cells dependent on its paralogous gene COPZ1","volume":"108","author":"Shtutman","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.bcp.2024.116254_b0380","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.febslet.2009.07.032","article-title":"The COPI system: Molecular mechanisms and function","volume":"583","author":"Beck","year":"2009","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.bcp.2024.116254_b0385","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1083\/jcb.200810098","article-title":"Early endosomes and endosomal coatomer are required for autophagy","volume":"185","author":"Razi","year":"2009","journal-title":"J. Cell Biol."},{"issue":"476","key":"10.1016\/j.bcp.2024.116254_b0390","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.canlet.2020.02.011","article-title":"COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death","volume":"28","author":"Di Marco","year":"2020","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0395","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: Still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0400","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J. Gen. Physiol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0405","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","article-title":"Tumor cell metabolism: Cancer\u2019s Achilles\u2019 heel","volume":"13","author":"Kroemer","year":"2008","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0410","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cmet.2012.10.017","article-title":"Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells","volume":"16","author":"Favaro","year":"2012","journal-title":"Cell Metab."},{"issue":"12","key":"10.1016\/j.bcp.2024.116254_b0415","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1158\/2159-8290.CD-16-0615","article-title":"Targeting cancer metabolism: Dietary and pharmacologic interventions","volume":"6","author":"Vernieri","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0420","first-page":"683","article-title":"Metformin and cancer: An existing drug for cancer prevention and therapy","volume":"15","author":"Zi","year":"2018","journal-title":"Oncol Lett."},{"issue":"2","key":"10.1016\/j.bcp.2024.116254_b0425","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00109-015-1377-9","article-title":"Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy","volume":"94","author":"Zois","year":"2016","journal-title":"J. Mol. Med. Berl. Ger."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0430","first-page":"143","article-title":"Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer","volume":"42","author":"de Heer","year":"2023","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.bcp.2024.116254_b0435","doi-asserted-by":"crossref","unstructured":"Kakhlon O, Ferreira I, Solmesky LJ, Khazanov N, Lossos A, Alvarez R, et al. Guaiacol as a drug candidate for treating adult polyglucosan body disease. JCI Insight. 2018 Sep 6;3(17):e99694, 99694.","DOI":"10.1172\/jci.insight.99694"},{"key":"10.1016\/j.bcp.2024.116254_b0440","article-title":"Targeting pyrimidine metabolism in the era of precision cancer medicine","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2024.116254_b0445","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ccell.2022.07.012","article-title":"A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma","volume":"40","author":"Pal","year":"2022","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.bcp.2024.116254_b0450","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","article-title":"The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies","volume":"33","author":"Christian","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bcp.2024.116254_b0455","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nrc3985","article-title":"The multifaceted functions of sirtuins in cancer","volume":"15","author":"Chalkiadaki","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0460","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ccell.2019.05.002","article-title":"Non-oncogene addiction to SIRT3 plays a critical role in lymphomagenesis","volume":"35","author":"Li","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0465","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/2643-3230.BCD-20-0168","article-title":"SIRT5 is a druggable metabolic vulnerability in acute myeloid leukemia","volume":"2","author":"Yan","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"9","key":"10.1016\/j.bcp.2024.116254_b0470","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41388-020-01637-w","article-title":"Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer","volume":"40","author":"Abril","year":"2021","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bcp.2024.116254_b0475","first-page":"1954","article-title":"Epigenetic mechanisms and the hallmarks of cancer: an intimate affair","volume":"10","author":"Darwiche","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116254_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: Key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0485","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2012.06.008","article-title":"Cancer genetics and epigenetics: Two sides of the same coin?","volume":"22","author":"You","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0490","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cell.2013.03.008","article-title":"Interplay between the cancer genome and epigenome","volume":"153","author":"Shen","year":"2013","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bcp.2024.116254_b0495","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/bies.201000055","article-title":"Replication stress, a source of epigenetic aberrations in cancer?","volume":"32","author":"Jasencakova","year":"2010","journal-title":"BioEssays News Rev. Mol. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0500","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-021-00721-x","article-title":"Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends","volume":"28","author":"Nepali","year":"2021","journal-title":"J. Biomed. Sci."},{"issue":"17","key":"10.1016\/j.bcp.2024.116254_b0505","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.febslet.2012.04.045","article-title":"The bromodomain interaction module","volume":"586","author":"Filippakopoulos","year":"2012","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.bcp.2024.116254_b0510","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1189\/jlb.2RI0616-250R","article-title":"Bromodomain 4: A cellular Swiss army knife","volume":"100","author":"Devaiah","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2024.116254_b0515","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/stem.3454","article-title":"Emerging roles of bromodomain protein 4 in regulation of stem cell identity","volume":"39","author":"Dey","year":"2021","journal-title":"Stem Cells Dayt Ohio"},{"key":"10.1016\/j.bcp.2024.116254_b0520","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1101\/sqb.2016.81.031039","article-title":"The essential transcriptional function of BRD4 in acute myeloid leukemia","volume":"81","author":"Roe","year":"2016","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"issue":"17","key":"10.1016\/j.bcp.2024.116254_b0525","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/.20.17.6537-6549.2000","article-title":"A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition","volume":"20","author":"Dey","year":"2000","journal-title":"Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.bcp.2024.116254_b0530","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1128\/MCB.22.11.3794-3802.2002","article-title":"Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4","volume":"22","author":"Houzelstein","year":"2002","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0535","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.celrep.2014.08.055","article-title":"Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes","volume":"9","author":"Di Micco","year":"2014","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.bcp.2024.116254_b0540","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/13543784.2017.1335711","article-title":"Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)","volume":"26","author":"Braun","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"12","key":"10.1016\/j.bcp.2024.116254_b0545","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.18632\/oncotarget.733","article-title":"Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML","volume":"3","author":"Herrmann","year":"2012","journal-title":"Oncotarget"},{"issue":"7370","key":"10.1016\/j.bcp.2024.116254_b0550","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"issue":"40","key":"10.1016\/j.bcp.2024.116254_b0555","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0560","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","article-title":"BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia","volume":"58","author":"Roe","year":"2015","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0565","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bcp.2024.116254_b0570","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/ajh.26650","article-title":"BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia","volume":"97","author":"Peter","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.bcp.2024.116254_b0575","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1158\/2159-8290.CD-16-1297","article-title":"PAX3-FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability","volume":"7","author":"Gryder","year":"2017","journal-title":"Cancer Discov."},{"issue":"4 Pt 1","key":"10.1016\/j.bcp.2024.116254_b0580","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1203\/00006450-199904010-00015","article-title":"Myc oncogene expression and nude mouse tumorigenicity and metastasis formation are higher in alveolar than embryonal rhabdomyosarcoma cell lines","volume":"45","author":"Kouraklis","year":"1999","journal-title":"Pediatr. Res."},{"issue":"5","key":"10.1016\/j.bcp.2024.116254_b0585","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/1535-7163.MCT-15-0567","article-title":"The bromodomain BET inhibitor JQ1 suppresses tumor angiogenesis in models of childhood sarcoma","volume":"15","author":"Bid","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bcp.2024.116254_b0590","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","article-title":"Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors","volume":"4","author":"Shern","year":"2014","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0051-2","article-title":"Rhabdomyosarcoma","volume":"5","author":"Skapek","year":"2019","journal-title":"Nat. Rev. Dis. Primer"},{"issue":"7","key":"10.1016\/j.bcp.2024.116254_b0600","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.3390\/ijms23073581","article-title":"Bromodomain inhibitor JQ1 provides novel insights and perspectives in rhabdomyosarcoma treatment","volume":"23","author":"Marchesi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116254_b0605","doi-asserted-by":"crossref","DOI":"10.1038\/s44319-023-00033-1","article-title":"BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma","author":"Das","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bcp.2024.116254_b0610","doi-asserted-by":"crossref","unstructured":"Yi Y, Ge S. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. J Hematol OncolJ Hematol Oncol. 2022 Mar 24;15(1):35.","DOI":"10.1186\/s13045-022-01251-1"},{"key":"10.1016\/j.bcp.2024.116254_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105335","article-title":"Targeting LSD1 for acute myeloid leukemia (AML) treatment","volume":"164","author":"Zhang","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.bcp.2024.116254_b0620","doi-asserted-by":"crossref","first-page":"e1000190","DOI":"10.1371\/journal.pgen.1000190","article-title":"The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure","volume":"4","author":"Jones","year":"2008","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bcp.2024.116254_b0625","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.917125","article-title":"The role of DOT1L in normal and malignant hematopoiesis","volume":"10","author":"Arnold","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116254_b0630","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.bcp.2024.116254_b0635","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1101\/gad.2057811","article-title":"The diverse functions of Dot1 and H3K79 methylation","volume":"25","author":"Nguyen","year":"2011","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0640","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2024.116254_b0645","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/cancers13040642","article-title":"Elucidating the importance of DOT1L recruitment in MLL-AF9 leukemia and hematopoiesis","volume":"13","author":"Grigsby","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2024.116254_b0650","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: From biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0655","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/cas.14311","article-title":"Synthetic lethal therapy based on targeting the vulnerability of SWI\/SNF chromatin remodeling complex-deficient cancers","volume":"111","author":"Sasaki","year":"2020","journal-title":"Cancer Sci."},{"issue":"21","key":"10.1016\/j.bcp.2024.116254_b0660","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/s41388-021-01781-x","article-title":"Exploiting vulnerabilities of SWI\/SNF chromatin remodelling complexes for cancer therapy","volume":"40","author":"Wanior","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0665","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13148-019-0734-x","article-title":"Epigenetic synthetic lethality approaches in cancer therapy","volume":"11","author":"Yang","year":"2019","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.bcp.2024.116254_b0670","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2019.09.018","article-title":"Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI\/SNF-defective cancers","volume":"61","author":"Chabanon","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2024.116254_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115727","article-title":"Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors","volume":"215","author":"Lanzi","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166746","article-title":"Targeting the tumor microenvironment: Potential strategy for cancer therapeutics","volume":"1869","author":"Babar","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0685","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal CCS"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0690","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tranon.2019.10.001","article-title":"Targeting tumor microenvironment by small-molecule inhibitors","volume":"13","author":"Zhong","year":"2020","journal-title":"Transl. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2024.116254_b0695","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0700","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0705","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12672-023-00793-1","article-title":"Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer","volume":"14","author":"He","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bcp.2024.116254_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108469","article-title":"Immunotherapy of cancer by targeting regulatory T cells","volume":"104","author":"Chen","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2024.116254_b0715","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0720","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41574-018-0126-x","article-title":"The obese adipose tissue microenvironment in cancer development and progression","volume":"15","author":"Quail","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"10.1016\/j.bcp.2024.116254_b0725","first-page":"763","article-title":"Classifying the linkage between adipose tissue inflammation and tumor growth through cancer-associated adipocytes","volume":"43","author":"Song","year":"2020","journal-title":"Mol. Cells"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0730","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-020-00257-6","article-title":"Cancer-associated adipocytes as immunomodulators in cancer","volume":"9","author":"Wu","year":"2021","journal-title":"Biomark. Res."},{"issue":"10","key":"10.1016\/j.bcp.2024.116254_b0735","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41419-023-06230-z","article-title":"Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy","volume":"14","author":"Huang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"15","key":"10.1016\/j.bcp.2024.116254_b0740","doi-asserted-by":"crossref","first-page":"e158450","DOI":"10.1172\/JCI158450","article-title":"Cellular senescence: A key therapeutic target in aging and diseases","volume":"132","author":"Zhang","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0745","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bcp.2024.116254_b0750","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.devcel.2023.05.010","article-title":"Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies","volume":"58","author":"D\u2019Ambrosio","year":"2023","journal-title":"Dev. Cell."},{"key":"10.1016\/j.bcp.2024.116254_b0755","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pharmthera.2018.08.006","article-title":"Senescence and senotherapeutics: A new field in cancer therapy","volume":"193","author":"Myrianthopoulos","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2024.116254_b0760","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","article-title":"Senolytic therapy in mild Alzheimer\u2019s disease: a phase 1 feasibility trial","volume":"29","author":"Gonzales","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0765","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.bcp.2024.116254_b0770","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3390\/cells9051313","article-title":"Metalloproteinases and their inhibitors: Potential for the development of new therapeutics","volume":"9","author":"Raeeszadeh-Sarmazdeh","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2024.116254_b0775","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2024.116254_b0780","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0785","first-page":"171","article-title":"Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance","volume":"42","author":"Kao","year":"2023","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"issue":"4","key":"10.1016\/j.bcp.2024.116254_b0790","first-page":"1423","article-title":"Metformin inhibits gastric cancer via the inhibition of HIF1\u03b1\/PKM2 signaling","volume":"5","author":"Chen","year":"2015","journal-title":"Am. J. Cancer Res."},{"issue":"21","key":"10.1016\/j.bcp.2024.116254_b0795","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0800","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.bcp.2024.116254_b0805","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41420-022-00930-9","article-title":"Targeting tumor innervation: premises, promises, and challenges","volume":"8","author":"Li","year":"2022","journal-title":"Cell Death Discov."},{"issue":"7","key":"10.1016\/j.bcp.2024.116254_b0810","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2024.116254_b0815","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1158\/2159-8290.CD-16-0217","article-title":"BRD4 connects enhancer remodeling to senescence immune surveillance","volume":"6","author":"Tasdemir","year":"2016","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bcp.2024.116254_b0820","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116254_b0825","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568931","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: Implications for immunotherapy treatment","volume":"11","author":"Hudson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116254_b0830","doi-asserted-by":"crossref","unstructured":"Vlodavsky I, Sanderson RD, Ilan N, editors. Heparanase: From Basic Research to Clinical Applications [Internet]. Cham: Springer International Publishing; 2020 [cited 2024 Feb 6]. (Advances in Experimental Medicine and Biology; vol. 1221). Available from: http:\/\/link.springer.com\/10.1007\/978-3-030-34521-1.","DOI":"10.1007\/978-3-030-34521-1"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224002375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224002375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:44:40Z","timestamp":1777380280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224002375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":166,"alternative-id":["S0006295224002375"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116254","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-oncogene dependencies: Novel opportunities for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116254"}}